Lantus and Taltz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lantus (insulin glargine recombinant) and Taltz (ixekizumab). Common drug interactions include psoriasis among females and arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Lantus and Taltz. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Taltz?

Taltz has active ingredients of ixekizumab. eHealthMe is studying from 29,777 Taltz users. Check the latest studies of Taltz.



On Jul, 17, 2026

48 people who take Lantus and Taltz together, and have interactions are studied.

Lantus and Taltz drug interactions.

What are the common drug interactions of Lantus and Taltz, by gender? *:

female:

  1. Psoriasis (immune-mediated disease that affects the skin)
  2. Injection site pain
  3. Blood glucose increased
  4. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  5. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  6. Glycosylated haemoglobin increased
  7. Pneumococcal sepsis (pneumococcal sepsis is a serious medical condition where bacteria, specifically streptococcus pneumoniae)
  8. Purpura fulminans (destructive infections that involve both skin and soft tissues)
  9. Septic shock (shock due to blood infection)
  10. Asthma

male:

  1. Arthralgia (joint pain)
  2. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  3. Therapeutic response decreased (less preventive response)
  4. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  5. Blood lactic acid increased
  6. Blood ph decreased
  7. Diabetic hyperosmolar coma (diabetes coma due to extremely high blood sugar (glucose) levels; extreme lack of water (dehydration))
  8. Glycosylated haemoglobin increased
  9. Groin abscess (pus in groin)
  10. Haematemesis (vomiting of blood)

What are the common drug interactions of Lantus and Taltz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  2. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  3. Pneumococcal sepsis (pneumococcal sepsis is a serious medical condition where bacteria, specifically streptococcus pneumoniae)
  4. Purpura fulminans (destructive infections that involve both skin and soft tissues)
  5. Septic shock (shock due to blood infection)
  6. Urinary tract infection
  7. Gastric ulcer (stomach ulcer)
  8. Ovarian cyst ruptured (tear in fluid filled sac of the ovary)
  9. Psoriasis (immune-mediated disease that affects the skin)

30-39:

  1. Asthenia (weakness)
  2. Fatigue (feeling of tiredness)

40-49:

  1. Diabetic hyperosmolar coma (diabetes coma due to extremely high blood sugar (glucose) levels; extreme lack of water (dehydration))
  2. Groin abscess (pus in groin)
  3. Chest pain
  4. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  5. Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
  6. Hepatic failure (liver failure)
  7. Hepatitis alcoholic (inflammation of the liver due to alcohol)
  8. Infection
  9. Inflammation
  10. Irritable bowel syndrome

50-59:

  1. Hypertension (high blood pressure)
  2. Joint range of motion decreased (disease of joint movement)
  3. Joint swelling
  4. Nodule (a growth of abnormal tissue)
  5. Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)
  6. Rheumatoid nodule (a local swelling or tissue lump with rheumatoid disease)
  7. Tenderness (pain or discomfort when an affected area is touched)
  8. Therapeutic response decreased (less preventive response)
  9. Injection site pain
  10. Blood lactic acid increased

60+:

  1. Psoriasis (immune-mediated disease that affects the skin)
  2. Arthropathy
  3. Asthma
  4. Blood glucose increased
  5. Glycosylated haemoglobin increased
  6. Injection site pain
  7. Nasopharyngitis (inflammation of the nasopharynx)

What are the existing conditions these people have? *

  1. Psoriasis (immune-mediated disease that affects the skin): 23 people, 47.92%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 10.42%
  3. Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 4 people, 8.33%
  4. Intertrigo (inflammation (rash) of the body folds (adjacent areas of skin)): 4 people, 8.33%
  5. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and Taltz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lantus and Taltz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Taltz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lantus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Taltz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant and ixekizumab (the active ingredients of Lantus and Taltz, respectively), and Lantus and Taltz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: